William Blair Has Pessimistic Outlook of CGEM Q3 Earnings

Key Points

• William Blair has significantly lowered its Q3 2025 earnings per share estimate for Cullinan Therapeutics from ($0.72) to ($0.86), aligning with expectations of worsening performance for the company.
• The latest quarterly results showed Cullinan Therapeutics missed the consensus estimate by posting earnings of ($1.07) per share, compared to the expected ($0.83).
• Analysts remain divided on the stock, with a total of five rated it as "buy," but various price targets range significantly from $22.00 to $33.00, reflecting differing outlooks on company performance.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - William Blair decreased their Q3 2025 EPS estimates for shares of Cullinan Therapeutics in a research note issued to investors on Thursday, August 7th. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($0.86) for the quarter, down from their previous estimate of ($0.72). The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. William Blair also issued estimates for Cullinan Therapeutics' Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.85) EPS, FY2027 earnings at ($3.57) EPS and FY2028 earnings at ($4.21) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.24).

Several other equities analysts also recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th. UBS Group dropped their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Finally, Stifel Nicolaus assumed coverage on shares of Cullinan Therapeutics in a research note on Wednesday, June 11th. They set a "buy" rating and a $22.00 target price for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $30.00.

Cullinan Therapeutics Price Performance

Shares of Cullinan Therapeutics stock opened at $7.30 on Monday. Cullinan Therapeutics has a fifty-two week low of $6.85 and a fifty-two week high of $19.89. The firm has a market capitalization of $430.81 million, a P/E ratio of -2.26 and a beta of -0.08. The company's 50 day moving average price is $8.05 and its two-hundred day moving average price is $8.36.

Hedge Funds Weigh In On Cullinan Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Brooklyn Investment Group purchased a new stake in shares of Cullinan Therapeutics in the 1st quarter worth about $34,000. Federated Hermes Inc. lifted its position in shares of Cullinan Therapeutics by 67.0% in the 4th quarter. Federated Hermes Inc. now owns 3,802 shares of the company's stock worth $46,000 after purchasing an additional 1,525 shares during the period. GAMMA Investing LLC lifted its position in shares of Cullinan Therapeutics by 1,214.8% in the 1st quarter. GAMMA Investing LLC now owns 6,995 shares of the company's stock worth $53,000 after purchasing an additional 6,463 shares during the period. Virtus ETF Advisers LLC increased its stake in shares of Cullinan Therapeutics by 37.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company's stock worth $71,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Cullinan Therapeutics in the 4th quarter worth about $77,000. Institutional investors own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.